Three Key Things Every CAR-T Investor Should Observe – The Motley Loser
Three Key Things Every CAR-T Investor Should Observe A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could ultimately hit the market later this year. First-to-market advantage will likely to go Novartis (NYSE:NVS) with its drug named CTL019. Recently, a panel of FDA advisors unanimously recommended approval for CTL019, which will likely receive a final stamp of approval from the agency by early October.
